TREAT - Darbepoetin in DM2 & CKD

| No Comments
TREAT. A Trial of Darbepoetin Alfa in Type 2 Diabetes and Chronic Kidney Disease. NEJM 2009; 361: 2019.

Background: Study of the outcome effect of increasing hemoglobin levels in patients with type 2 diabetes and CKD.

Methods: Multi-national, randomized, double-blind, placebo-controlled trial. Included patients with DM2, CKD (GFR 20-60 [MDRD]), anemia (Hb < 11.0), and transferrin saturation of 15%. Excluded uncontrolled HTN, kidney transplant, current use of IV ABx, chemo, XRT, cancer (x BCCA or SCCA of the skin), HIV, active bleeding, heme disorder, or pregnancy. n = 4038.

Treatment: darbepoetin alfa to achieve Hb of 13 g/dL v rescue darbepoetin when Hb < 9.0.

Results: darbepoetin v placebo
Death (any cause): 20.5 v 19.5%, p = 0.48
MI: 6.2 v 6.4%, p = 0.73
Stroke: 5.0 v 2.6, p = <0.001, NNH = 42
Heart failure: 10.2 v 11.3, p = 0.24
Myocardial ischemia: 2.0 v 2.4, p = 0.40
ESRD: 16.8 v 16.3, p = 0.83

Additional reading:







RECENT ADDITIONS



Question of the Day | More QOD

Anemia, when to transfuse?

| No Comments
We know from the Hebert et al (NEJM 1999, Crit Care Med 2001) that most critically ill patients with anemia should be transfused to maintain a hemoglobin of 7.0-9.0 g/dL and Wu et al (NEJM 2001) showed that elderly people with myocardial infarctions should be transfused to maintain a hematocrit between 30-33%, therefore, should critically ill patients with ESRD be transfused to maintain a hemoglobin between 11-12.0 g/dL, and if not, what should that target be?
Highlighted Guidelines | More Guidelines

NKF/KDOQI: Anemia in Chronic Kidney Disease

| No Comments
2.1.2 In the opinion of the Work Group, in dialysis and nondialysis patients with CKD receiving ESA therapy, the selected Hb target should generally be in the range of 11.0 to 12.0 g/dL. (Clinical Practice RECOMMENDATION)

2.1.3 In dialysis and nondialysis patients with CKD receiving ESA therapy, the Hb target should not be greater than 13.0 g/dL. (Clinical Practice GUIDELINE - MODERATELY STRONG EVIDENCE)

KDOQI Clinical Practice Guideline and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease: 2007 Update of Hemoglobin Target

Heme 1

| 3 Comments

A 68 year old man with hypertesion treated with HCTZ comes for an annual physical exam.

On examination, temperature is normal, BP is 139/84, HR 87 bpm, and RR 16/min. The patient has rosy cheeks. There is no JVD, cardiopulmonary exam is normal, and spleen tip is palpable just below the left costal margin.

Lab

Hematocrit: 61%

Leukocyte count: 11,200/microL
Platelet count: 405,000/microL
Erythropoietin: 10 mU/mL
Arterial oxygen saturation: 96% (on room air)
Cytogenetic studies: positive JAK2 mutation

 

What is the most appropriate therapy?

A) Therapeutic phlebotomy
B) Therapeutic phlebotomy plus anagrelide
C) Therapeutic phlebotomy plus aspirin
D) Therapeutic phlebotomy plus hydroxyurea
Image Challenge | More Image Challenges

Image YWG061022

| No Comments

This is an 87 year old man who has a protracted hospital stay complicated by ESBL and VRE UTI, c. difficile colitis, MRSA and pseudomonal pneumonia who has had chronic anemia now having acute respiratory distress and rapidly worsening anemia (hemoglobin drop from 9.8 g/dL to 6.9 g/dL). He has had hematuria for five days. A CT scan was done, see below, what is the next step?

YWG.jpg

EKG Challenge | More EKG Challenges

EKG C2

| 1 Comment
This is a 53 year old man who uses crack cocaine and has hypertension and hepatitis C. He was seen at another hospital seven days prior to this admission with chest pain. His EKG is provided below. He was discharged on indomethacin, colchicine, and ciprofloxacin. He has continued chest pain and malaise. His troponin level is 1.85 ng/mL. He is admitted to the telemetry monitoring and has continued chest pain. His morning EKG is provided below and now his troponin level has gone from 3.58 ng/mL to 6.20 ng/mL.

What should you do next? 

ekg5652 120709.jpg
12-07-2009

ekg5652 121509.jpg
12-15-09

ekg5652 121609-2.jpg
12-16-09

May 2010

Sun Mon Tue Wed Thu Fri Sat
            1
2 3 4 5 6 7 8
9 10 11 12 13 14 15
16 17 18 19 20 21 22
23 24 25 26 27 28 29
30 31          

Recent Image Challenge

  • YWG.jpg
  • MZ - CT2.jpg
  • MZ - CT1.jpg
  • MZ - CT3.jpg
  • staph.jpg
  • CM091948 - CT.jpg
  • CM091948 - CT2.jpg
  • CM091948 - CXR.jpg

Recent IC Attempts

  • Yelenka: Well, there has to be a connection between the biliary read more
  • Elena: Miliary TB is named so because the nodules are the read more
  • cdub: Miliary TB read more

Recent EKG Challenge

  • ekg5652 121509.jpg
  • ekg5652 121609-2.jpg
  • ekg5652 120709.jpg
  • ekg1.jpg

Recent SMJR Assets

  • bnp-nomogram.jpg
  • DLSC.jpg
  • role of echo.jpg
  • reitan trail test.gif
  • ppv2.jpg
  • VPW.jpg
  • PPV.jpg
  • s3 and ss- jama.gif
  • s3 - jama.gif
  • s3 and ss.gif

Useful Links

Reading Lists

Recent JR Comments

  • Elena: Number needed to harm is a little concerning... I think read more
  • Patrick: Your point is well taken. However, the value of BNP, read more
  • jpjapes: Absolute values are one means of assessing pts in HF read more

Recent QOD Comments

  • mbazylewicz: Ok, here is my understanding from reading UpToDate: Parapneumonic effusion read more
  • Patrick: Initially, Aspergillosis was considered an AIDS-defining oppurtunistic infection in the read more
  • AH: Liver failure due to methimazole use. Woeber KA. Methimazole-induced hepatotoxicity. read more

Recent "G" Comments

  • Patrick: Guidelines are meant to be guidelines. In the IDSA recommendation, read more
  • Alifeya: an example, 80 y/o nursing home resident with severe dementia read more
  • Patrick: The IDSA guidelines for uncomplicated cystitis excluded studies where >2% read more

Recent MCQ Responses

  • joey: c read more
  • Paul Ramirez: C. This pt has polycythemia vera. The rosy cheeks, splenomegaly, read more
  • Alifeya: Pt has already developed Eissenmenger's physiology, its too late to read more

Clinical Archives